Archive for December 2019

AAHP’s Views on Aspects of FDA’s Revised Draft Guidance

Since 2015, the Food and Drug Administration (FDA) has been engaged in a reevaluation of Compliance Policy Guide 400.400, Conditions under Which Homeopathic Drugs May Be Marketed. FDA issued a new draft policy in December 2017, and, after a public comment period, it issued a revised draft in October 2019, readm more…

Read More

AAHP 2019: Reawakening the Regulatory and Retail Dialog

By Mark Land, AAHP President This year marks the fifth year in a cycle of regulatory review of homeopathic drug product labeling, safety, and quality. AAHP has been there for the industry as an advocate and representative over the entire duration. In 2019 AAHP provided direction and regulatory thought-leadership within readm more…

Read More